Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
426 ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.